Investment13 Nov 2025, 06:46 pm
Concord Biotech Ltd. Approves Q2 and HY Results for FY2025-2026, Announces Investment in Celliimune Biotech and Solar Power Project
AI Summary
Concord Biotech Ltd. has approved the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025. The company has also announced its decision to invest in Celliimune Biotech Private Limited and a captive hybrid solar power project for its Limbasi Plant. The board has approved an investment of up to Rs. 10 Crores in the solar power project.
Key Highlights
- Approval of unaudited standalone and consolidated financial results for Q2 and HY ended September 30, 2025
- Planned investment in Celliimune Biotech Private Limited
- Approval to invest in a captive hybrid solar power project for the Limbasi Plant
- Investment amount capped at Rs. 10 Crores for the solar power project